|
Control group
|
Active group
|
p-value†
|
---|
HbA1c (%)
| | | |
Prior treatment
|
8.18 ± 1.33
|
8.53 ± 1.29
| |
After treatment
|
7.58 ± 1.06
|
7.39 ± 0.81
| |
p-value (baseline vs end)‡
|
<0.001
|
<0.001
| |
LS mean difference (95% CI)
|
0.53 (0.31-0.76)
|
<0.001
|
FBG (mg/dl)
| | | |
Prior treatment
|
168.9 ± 47.2
|
182.6 ± 57.1
| |
After treatment
|
148.5 ± 42.7
|
135.6 ± 34.5
| |
p-value(baseline vs end) ‡
|
<0.001
|
<0.001
| |
LS mean difference (95% CI)
|
27.85 (15.74-39.95)
|
<0.001
|
- †Statistically significant difference between the control and the active group.
- ‡Statistically significant difference in least squares means of HbA1c in each treatment group.
- CI confidence intervals.
- LS least squares.